(Q34666449)

3 August 2017

1 reference

title

Parkinson's disease: medical treatment of moderate to advanced disease (English)

1 reference

3 August 2017

1 reference

Oksana Suchowersky

1

1 reference

3 August 2017

1 July 2002

1 reference

Current Neurology and Neuroscience Reports

3 August 2017

1 reference

3 August 2017

2

1 reference

3 August 2017

4

1 reference

3 August 2017

310-316

1 reference

https://scigraph.springernature.com/pub.10.1007/s11910-002-0006-5

3 August 2017

0 references

cites work

Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men.

1 reference

https://api.crossref.org/works/10.1007%2FS11910-002-0006-5

Gastric emptying in Parkinson's disease: patients with and without response fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-002-0006-5

Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-002-0006-5

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-002-0006-5

Levodopa-induced dyskinesias are improved by fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-002-0006-5

Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-002-0006-5

An estimate of the incidence of depression in idiopathic Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-002-0006-5

Coexisting dementia and depression in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-002-0006-5

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-002-0006-5

Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-002-0006-5

Switching from pergolide to pramipexole in patients with Parkinson's disease

21 January 2018

1 reference

12 December 2020

Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon

1 reference

12 December 2020

A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group

1 reference

12 December 2020

SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.

1 reference

12 December 2020

Palliative and prophylactic benefits of continuously administered dopaminomimetics in Parkinson's disease.

1 reference

12 December 2020

Sinemet in Parkinson's disease: efficacy with and without food

1 reference

12 December 2020

1 reference

12 December 2020

Choosing dopamine agonists in Parkinson's disease

1 reference

12 December 2020

Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study

1 reference

12 December 2020

Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy

1 reference

12 December 2020

Parkinson's disease. Second of two parts

1 reference

12 December 2020

The emerging role of clozapine in the treatment of movement disorders

1 reference

12 December 2020

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

12 December 2020

A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group

1 reference

12 December 2020

A novel sublingual apomorphine treatment for patients with fluctuating Parkinson's disease.

1 reference

12 December 2020

Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD.

1 reference

12 December 2020

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group

1 reference

12 December 2020

Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease

1 reference

12 December 2020

Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease

1 reference

12 December 2020

Prevention of hip fracture in elderly people with use of a hip protector

1 reference

12 December 2020

Psychiatric side effects during the treatment of Parkinson's disease

1 reference

12 December 2020

Buspirone in levodopa-induced dyskinesias

1 reference

12 December 2020

Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease

1 reference

12 December 2020

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group

1 reference

12 December 2020

Clinical experience with duodenal infusions of levodopa for the treatment of motor fluctuations in Parkinson's disease

1 reference

12 December 2020

Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group

1 reference

12 December 2020

Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios

1 reference

12 December 2020

Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study

1 reference

12 December 2020

Treatment of Parkinson hypophonia with percutaneous collagen augmentation

1 reference

12 December 2020

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

12 December 2020

Prevalence of parkinsonian signs and associated mortality in a community population of older people.

1 reference

12 December 2020

A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy

1 reference

12 December 2020

Suppression of dyskinesias in advanced Parkinson's disease: moderate daily clozapine doses provide long-term dyskinesia reduction

1 reference

12 December 2020

Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?

1 reference

12 December 2020

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

12 December 2020

Tolcapone and fulminant hepatitis

1 reference

12 December 2020

Motor complications of chronic levodopa therapy in Parkinson's disease

1 reference

12 December 2020

Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease.

1 reference

12 December 2020

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

12 December 2020

Risperidone in Parkinson's disease

1 reference

12 December 2020

Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension

1 reference

12 December 2020

Pathophysiology of L-dopa-induced dyskinesias.

1 reference

12 December 2020

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

1 reference

12 December 2020

Entacapone. A review of its use in Parkinson's disease

1 reference

12 December 2020

10.1007/S11910-002-0006-5

Identifiers

DOI

1 reference

PubMed ID

12044250

Dimensions Publication ID

3 August 2017

0 references

1 reference

PubMed ID

12044250